Clark Estates’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.26M Sell
29,500
-15,368
-34% -$1.48M 0.76% 25
2026
Q2
$3.51M Hold
44,868
– – 0.81% 21
2026
Q1
$2.9M Hold
44,868
– – 0.7% 20
2025
Q4
$3.02M Hold
44,868
– – 0.73% 19
2025
Q3
$3.29M Hold
44,868
– – 0.75% 23
2025
Q2
$2.33M Hold
44,868
– – 0.52% 27
2025
Q1
$2.86M Sell
44,868
-17,132
-28% -$995K 0.61% 23
2024
Q4
$2.96M Buy
+62,000
New +$3.18M 0.57% 41

Other funds holding HALO

Clark Estates's HALO Position: Q3 2026 in Review

Clark Estates reduced its Halozyme (HALO) stake by 34% in Q3 2026, selling an estimated $1.48M and leaving 29,500 shares worth $3.26M. The position accounts for 0.76% of the portfolio, ranked #25.

Clark Estates first reported a position in HALO in Q4 2024 and has held it in 8 quarters since. The position peaked at $3.51M in Q2 2026. 636 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Clark Estates held 29,500 shares of Halozyme worth $3.26M as of Q3 2026.
  • Clark Estates sold 15,368 Halozyme shares in Q3 2026, an estimated $1.48M.
  • Halozyme made up 0.76% of Clark Estates's portfolio in Q3 2026, its #25 holding.
  • Clark Estates first reported a position in Halozyme in Q4 2024 and has held it in 8 quarters since.
  • Clark Estates's Halozyme position peaked at $3.51M in Q2 2026.
  • 636 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Clark Estates's 13F filing for Q3 2026, filed 10 Nov 2026.